The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Uwe PlatzbeckerDuring the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the new approaches for anemia in MDS.
What are the new approaches for anemia in MDS?
Anemia is one of the predominant clinical features of MDS. Standard of care includes erythropoiesis-stimulating agents to which around 40% of patients respond, leaving a large proportion of patients refractory to treatment. Uwe Platzbecker outlines the major clinical needs in this subset of patients and discusses alternative novel approaches to treating anemia in MDS.